These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9751377)

  • 1. Uncommon course of carcinoma of the prostate after radical prostatectomy and luteinizing hormone-releasing hormone analogue therapy.
    Pauer W; Eckerstorfer GM
    J Urol; 1998 Oct; 160(4):1432-3. PubMed ID: 9751377
    [No Abstract]   [Full Text] [Related]  

  • 2. [Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy].
    López López C; Quilez Fenoll JM; Gómez Ruiz JJ; López López AF; Romero Maroto YJ
    Arch Esp Urol; 1996 Oct; 49(8):819-23. PubMed ID: 9065279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR; Presti JC; Gill H; Brooks J; Hancock SL
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total cystoprostatectomy in the treatment of locally advanced prostate carcinoma.
    Sato K; Tsuchiya N; Habuchi T; Satoh S; Shimoda N; Kato T
    Aktuelle Urol; 2003 Jul; 34(4):259-61. PubMed ID: 14566679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced prostate cancer. Hormonal treatment.
    de la Haba-Rodríguez J
    Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
    [No Abstract]   [Full Text] [Related]  

  • 6. [Study of intermittent endocrine therapy in patients presenting with biologic recurrence after radical prostatectomy or radiotherapy].
    de la Taille A; Zerbib M; Conquy S; Amsellem-Ouazana D; Saighi D; Debré B
    Prog Urol; 2002 Apr; 12(2):240-7. PubMed ID: 12108338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical studies in prostatic carcinoma].
    Kumanov Kh; Tsvetkov M
    Khirurgiia (Sofiia); 1993; 46(5):6-8. PubMed ID: 7983831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of agonist analogues of luteinizing hormone--releasing hormone in the treatment of prostatic carcinoma].
    Gez E; Ben-Yosef R; Libson E; Biran S
    Harefuah; 1987 Mar; 112(5):239-41. PubMed ID: 3301586
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
    Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J; Altwein JE
    Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate cancer].
    Tanikawa T
    Rinsho Byori; 2001 Oct; 49(10):955-62. PubMed ID: 11769471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of prostatic cancer].
    J Urol (Paris); 1984; 90(10):619-48. PubMed ID: 6242517
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
    Schally AV
    BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up after triple treatment of prostate cancer stage pT3.
    Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
    Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic carcinoma of the prostate with leuprolide, an LHRH analogue.
    Smith JA
    Prog Clin Biol Res; 1985; 185A():279-85. PubMed ID: 3929267
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hormone treatment of prostate cancer in Norway].
    Johansen TE; Berg C
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2558-62. PubMed ID: 19023350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I; Miyake H; Hara S; Gotoh A; Eto H; Arakawa S; Kamidono S
    Hinyokika Kiyo; 2001 Jul; 47(7):453-8. PubMed ID: 11523127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.